Nasdaq: LUCY updates $2.68M at-the-market stock program
Rhea-AI Filing Summary
The company is updating its at-the-market common stock offering to allow sales of up to $2,679,217 of common stock through H.C. Wainwright & Co. under an existing sales agreement and shelf registration. This amount excludes approximately $1,202,269 of common stock already sold under earlier related prospectus supplements. The filing notes a public float of about $11,644,460, based on 3,298,714 shares held by non-affiliates at $3.53 per share as of June 20, 2025. The common stock trades on the Nasdaq Capital Market under the symbol LUCY, with a last reported price of $2.20 per share on August 14, 2025. Investors are directed to detailed risk factor discussions before purchasing shares.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the latest 424B5 prospectus supplement for LUCYW do?
The prospectus supplement updates the maximum amount of common stock that can be sold under the company’s at-the-market offering program, allowing sales of up to $2,679,217 of common stock through H.C. Wainwright & Co. under an existing Form S-3 registration.
How much common stock can the company now sell under its ATM program?
The company may offer and sell common stock with an aggregate offering price of up to $2,679,217 from time to time through H.C. Wainwright & Co. under the at-the-market sales agreement.
How much stock has already been sold under the prior prospectus supplements?
The filing states that approximately $1,202,269 of common stock has already been sold under the prior prospectus supplements pursuant to General Instruction I.B.6 of Form S-3.
What is the current public float of LUCY common stock mentioned in the filing?
The public float is reported as approximately $11,644,460, calculated from 3,298,714 shares of common stock held by non-affiliates at a price of $3.53 per share as of June 20, 2025.
Where is the company’s common stock listed and what was the recent trading price?
The common stock is listed on the Nasdaq Capital Market under the symbol LUCY. The last reported sale price was $2.20 per share on August 14, 2025.
Will the company file additional supplements for future at-the-market sales?
The document states that if the company becomes able to sell additional amounts under the sales agreement in accordance with General Instruction I.B.6 of Form S-3, it will file another prospectus supplement before making such additional sales.
What risks are highlighted for investors considering this common stock offering?
The supplement directs investors to read the “Risk Factors” section in the base prospectus and in documents incorporated by reference, which describe material risks associated with investing in the company’s common stock.
PROSPECTUS SUPPLEMENT
(To Prospectus Supplements Dated April 15, 2024, May 3, 2024, June 12, 2024 and July 11, 2024, to Prospectus Dated March 26, 2024)
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-276938
Up to $2,679,217
Common Stock
This prospectus supplement amends and supplements the information in the prospectus, dated March 26, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-276938), or the Registration Statement, as supplemented by our prospectus supplements, dated April 15, 2024, May 3, 2024, June 12, 2024 and July 11, 2024, or the Prior Prospectuses, relating to the offering, issuance and sale by us of our common stock, par value $0.00001 per share, or the Common Stock, from time to time that may be issued and sold under the at the market offering agreement, or the Sales Agreement, dated April 15, 2024, by and between us and H.C. Wainwright & Co., LLC, or Wainwright, as sales agent. This prospectus supplement should be read in conjunction with the Prior Prospectuses, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectuses. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectuses, and any future amendments or supplements thereto.
We are filing this prospectus supplement to amend the Prior Prospectuses to update the maximum amount of shares we are eligible to sell under our Registration Statement pursuant to General Instruction I.B.6 of Form S-3. As a result of these limitations and the current public float of our Common Stock, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our Common Stock having an aggregate offering price of up to $2,679,217 from time to time through Wainwright, which does not include the shares of Common Stock having an aggregate sales price of approximately $1,202,269 that were sold pursuant to the Prior Prospectuses to date. In the event that we may sell additional amounts under the Sales Agreement in accordance with General Instruction I.B.6, we will file another prospectus supplement prior to making such additional sales.
As of the date of this prospectus supplement, the aggregate market value of our outstanding Common Stock held by non-affiliates, or the public float, was approximately $11,644,460, which was calculated based on 3,298,714 shares of our outstanding Common Stock held by non-affiliates at a price of $3.53 per share, the closing price of our Common Stock on the Nasdaq Capital Market on June 20, 2025. During the 12 calendar months prior to, and including, the date of this prospectus supplement, we sold securities with an aggregate market value of approximately $1,202,269 pursuant to General Instruction I.B.6 of Form S-3.
Our Common Stock is listed on the Nasdaq Capital Market under the symbol “LUCY.” On August 14, 2025, the last reported sale price of our Common Stock on the Nasdaq Capital Market was $2.20 per share.
Investing in the offered securities involves a high degree of risk. Before buying any shares, you should read the discussion of material risks of investing in our Common Stock in “Risk Factors” beginning on page 9 of the prospectus, and in the risks discussed under similar headings in the documents incorporated by reference in this prospectus supplement and the prospectus, as they may be amended, updated or modified periodically in our reports filed with the Securities and Exchange Commission.
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
H.C. Wainwright & Co.
The date of this prospectus supplement is August 15, 2025